½ÃÀ庸°í¼­
»óǰÄÚµå
1786532

¼¼°èÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)

Peripheral Drug Eluting Balloon Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 273 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Persistence Market Research´Â ¼¼°è ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¶»ç º¸°í¼­¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦¸¦ Æ÷ÇÔÇÑ Áß¿äÇÑ ½ÃÀå ¿ªÇÐÀ» öÀúÈ÷ Æò°¡ÇÏ¿© ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ »ó¼¼ÇÑ ÅëÂûÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå ±Ô¸ð(2025³â) : 10¾ï 3,520¸¸ ´Þ·¯
  • ½ÃÀå ¿¹ÃøÄ¡(2032³â) : 18¾ï 4,430¸¸ ´Þ·¯
  • ¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2025-2032³â) : 8.6%

¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå - Á¶»ç ¹üÀ§

¸»ÃÊ ¾à¹° ¹æÃâ dz¼±(DEB)Àº Ç÷°ü¼ºÇü¼ú ½Ã¿¡ Ç×ÀçÇùÂøÁ¦¸¦ µ¿¸Æº®¿¡ Á÷Á¢ Àü´ÞÇÔÀ¸·Î½á ¸»Ãʵ¿¸ÆÁúȯ(PAD)ÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. DEB´Â dz¼± Ç÷°ü ¼ºÇü¼úÀÇ ±â°èÀû ÀÌÁ¡°ú ¾à¹° Àü´ÞÀÇ ¾à¸®ÇÐÀû ÀÌÁ¡À» °áÇÕÇÏ¿© ÀçÇùÂøÀÇ ¹ß»ý·üÀ» °¨¼Ò½ÃŰ°í ¿µ±¸ ÀÓÇöõÆ®ÀÇ Çʿ伺À» Á¦°ÅÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), Ä«Å×ÅÍ °Ë»ç½Ç¿¡ °ø±ÞµÇ¸ç ÁÖ·Î ´ëÅ𠹫¸­ µ¿¸Æ º´º¯°ú ¹«¸­ ÇÏ µ¿¸Æ º´º¯ÀÇ Ä¡·á¿¡ Àû¿ëµË´Ï´Ù. PADÀÇ ¼¼°è ºÎ´ã Áõ°¡, dz¼± ¼³°è ¹× ¾àÁ¦ ÄÚÆÃÀÇ ±â¼ú Çâ»ó, Àúħ½À Ä¡·á¿¡ ´ëÇÑ ±âÈ£ÀÇ °íÁ¶°¡ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :

¸»ÃÊ¿ë ¾à¹°¿ëÃâ dz¼± ¼¼°è ½ÃÀåÀº °í·ÉÈ­¿¡ ÀÇÇÑ ¸»Ãʵ¿¸ÆÁúȯÀÇ À¯º´·ü »ó½Â, ´ç´¢º´ ¹× Èí¿¬ Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ¹Ð·ÁÁö°í ÀÖ½À´Ï´Ù. ÆÄŬ¸®Å¹¼¿À̳ª ½Ã·Ñ¸®¹«½º¸¦ º£À̽º·Î ÇÑ Á¦Á¦ µî, ¾àÁ¦ ÄÚÆÃ ±â¼úÀÇ Áøº¸´Â ÀÓ»ó °á°ú¸¦ ´ëÆø °³¼±ÇØ, ÀÇ·á ÇöÀå¿¡¼­ÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ½ºÅÙÆ® À¯Ä¡¼úÀ» ´ëüÇÏ´Â ³·Àº ħ½ÀÀ¸·Î ºñ¿ë È¿À²ÀûÀÎ ¼±Åÿ¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼±Áø±¹ÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥°ú PAD¿Í ±× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡µµ ½ÅÈï ±¹°¡ÀÇ DEB ¼ö¿ä¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

ÀáÀçÀûÀÎ ¼ºÀå·Â¿¡µµ ºÒ±¸Çϰí, ÀÌ ½ÃÀåÀº Á¦Ç° ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ƯÈ÷ ¾à¹° ÄÚÆÃÀÇ ¾ÈÀü¼º ¹× È¿´É¿¡ °üÇÑ °úÁ¦ µî¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÆÄŬ¸®Å¹¼¿·Î ÄÚÆÃµÈ ÀåÄ¡¿Í Àå±âÀûÀÎ ¾ÈÀü¼º¿¡ ´ëÇÑ ÃÖ±ÙÀÇ ³íÀïÀº ÀÓ»óÀÇ¿Í ±ÔÁ¦ ´ç±¹ÀÇ ¿ì·Á¸¦ ³ôÀ̰í ä¿ë·ü¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³¹ß µµ»ó Áö¿ª¿¡¼­´Â Àåºñ ºñ¿ëÀÌ ³ô°í »óȯµµ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ º¸±Þ¿¡´Â ÇѰ谡 ÀÖ½À´Ï´Ù. ¶ÇÇÑ º£¾î dz¼±À̳ª ½ºÅÙÆ®¿Í °°Àº ´ëü Ä¡·á¹ýÀÇ Á¸Àçµµ ½ÃÀå °æÀï»óÀÇ ¾Ð·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ

¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀåÀº ÄÚÆÃ ±â¼úÀÇ Çõ½Å, ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ÁøÃâ, ¿µ»ó Áø´Ü ¹× ³»ºñ°ÔÀÌ¼Ç ±â¼ú°úÀÇ ÅëÇÕ¿¡ ÀÇÇÑ Ä¡·á ¼ºÀûÀÇ Çâ»ó µî¿¡ ÀÇÇØ Å« ºñÁî´Ï½º ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¾à¹° ¹æÃâ ÇÁ·ÎÆÄÀÏÀÌ °³¼±µÇ°í »ýüÀûÇÕ¼ºÀÌ ¶Ù¾î³­ Â÷¼¼´ë DEBÀÇ °³¹ß·Î »õ·Î¿î ¼ö¿ä¸¦ ĸóÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ¿¬±¸±â°ü°úÀÇ ¿¬°è¿¡ ÀÇÇØ º¸´Ù ±¤¹üÀ§ÇÑ ÀÓ»ó»ç¿ëÀ» µÞ¹ÞħÇÏ´Â È®½ÇÇÑ µ¥ÀÌÅ͸¦ ¾òÀ» ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó ¼ºÀåÀº ½ÃÀå ħÅõ¿Í ¼ºÀåÀÇ »õ·Î¿î ±æÀ» ¿­¾îÁÝ´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • Á¦Ç° °³¹ß°ú ä¿ë¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾à¹° À¯Çü°ú ÇØºÎÇÐÀû ¿ëµµ´Â?
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°ú ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á´Â ½ÃÀå µ¿Çâ°ú ÀÓ»ó »ç¿ë¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?
  • ¸»ÃÊ DEBs ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾î¶² ±â¾÷ÀÌ¸ç °æÀï·ÂÀ» °­È­Çϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
  • °¢ Áö¿ªÀÇ »õ·Î¿î µ¿Çâ°ú Àå±âÀûÀÎ ¼ºÀå Àü¸ÁÀº?

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
  • ¹ë·ùüÀÎ ºÐ¼®
  • °Å½Ã°æÁ¦ ¿äÀÎ
    • ¼¼°è GDP Àü¸Á
    • ¼¼°è °Ç¼³ ¾÷°èÀÇ °³¿ä
    • ¼¼°èÀÇ ±¤¾÷ »ê¾÷ÀÇ °³¿ä
  • ¿¹Ãø ¿äÀÎ- °ü·Ã¼º°ú ¿µÇâ
  • COVID-19ÀÇ ¿µÇâ Æò°¡
  • PESTLE ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÁöÁ¤ÇÐÀû ±äÀå: ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • ±ÔÁ¦¿Í ±â¼úÀÇ »óȲ

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • µ¿Çâ

Á¦4Àå °¡°Ý µ¿Ç⠺м®, 2019³â-2032³â

  • Áö¿ªº° °¡°Ý ºÐ¼®
  • ºÎ¹®º° °¡°Ý
  • °¡°Ý ¿µÇâ¿äÀÎ

Á¦5Àå ¼¼°èÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ¼¼°èÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á: ¾àÁ¦ ÄÚÆÃ
    • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
    • ÀǾàǰ ÄÚÆÃº° ½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, ¾àÁ¦ ÄÚÆÃº°, 2025³â-2032³â
      • Paclitaxel ¾àÁ¦ ÄÚÆÃ
      • Sirolimus ¾àÁ¦ ÄÚÆÃ
    • ½ÃÀå ¸Å·Â ºÐ¼® : ¾àÁ¦ ÄÚÆÃ
  • ¼¼°èÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ÀûÀÀÁõ
    • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
    • 2019³â-2024³â¿¡ À־ÀÇ ÀûÀÀÁõº° ½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®
    • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, ÀûÀÀÁõº°, 2025³â-2032³â
      • ¸»Ãʵ¿¸ÆÁúȯ
      • ¸»ÃÊ µ¿¸Æ·ù
      • ½ºÅÙÆ® ³» ÀçÇùÂø
    • ½ÃÀå ¸Å·Â ºÐ¼® : ÀûÀÀÁõ
  • ¼¼°èÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : µ¿¸Æ À¯Çü
    • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
    • µ¿¸Æ À¯Çüº° ½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, µ¿¸Æ À¯Çüº°, 2025³â-2032³â
      • °æµ¿¸Æ
      • ÆèÆË µ¿¸Æ
      • Àå°ñµ¿¸Æ
      • ÀÎÇÁ¶óÆË µ¿¸Æ
    • ½ÃÀå ¸Å·Â ºÐ¼® : µ¿¸Æ À¯Çü
  • ¼¼°è ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ÃÖÁ¾ »ç¿ëÀÚ
    • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
    • ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, ÃÖÁ¾ »ç¿ëÀÚº°, 2025³â-2032³â
      • º´¿ø
      • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)/¿Ü·¡ ȯÀÚ
      • ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç
    • ½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚ

Á¦6Àå ¼¼°èÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : Áö¿ª

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • Áö¿ªº° ½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, 2019³â-2024³â
  • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, Áö¿ªº°, 2025³â-2032³â
    • ºÏ¹Ì
    • À¯·´
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¸Å·Â ºÐ¼® :Áö¿ª

Á¦7Àå ºÏ¹Ì ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

Á¦8Àå À¯·´ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

Á¦9Àå µ¿¾Æ½Ã¾ÆÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

Á¦10Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸»ÃÊ ¾à¹° ¹æÃâ dz¼± ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
  • ½ÃÀå ±¸Á¶
    • °æÀï °­µµ ¸ÅÇÎ
    • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Cook Medical Inc.
    • MicroPort Scientific Corporation(Endovastec(TM))
    • Medtronic Plc.
    • Cardinal Health, Inc.
    • B. Braun Melsungen AG
    • BIOTRONIK SE &Co. KG
    • Becton, Dickinson and Company
    • WL Gore &Associates Inc.
    • Getinge AB
    • Terumo Corp
    • Kyoto Medical Planning Co Ltd
    • iVascular SLU
    • AMG International GmbH

Á¦14Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦
  • µÎÀÚ¾î ¹× ¾à¾î
SHW 25.08.14

Persistence Market Research has recently released a comprehensive report on the worldwide market for peripheral drug eluting balloons. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Peripheral Drug Eluting Balloons Market Size (2025E): USD 1035.2 Million
  • Projected Market Value (2032F): USD 1,844.3 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.6%

Peripheral Drug Eluting Balloons Market - Report Scope:

Peripheral drug eluting balloons (DEBs) are medical devices used to treat peripheral arterial disease (PAD) by delivering anti-restenotic drugs directly to the arterial walls during angioplasty. These devices combine the mechanical benefits of balloon angioplasty with the pharmacological advantages of drug delivery, reducing the incidence of restenosis and eliminating the need for permanent implants. The market serves hospitals, ambulatory surgical centers, and catheterization labs, with applications primarily in the treatment of femoropopliteal and below-the-knee arterial lesions. Market expansion is driven by the increasing global burden of PAD, technological improvements in balloon design and drug coatings, and growing preference for minimally invasive procedures.

Market Growth Drivers:

The global peripheral drug eluting balloons market is propelled by several key factors, including the rising prevalence of peripheral arterial disease due to aging populations and increasing incidences of diabetes and smoking. Advancements in drug coating technologies, such as paclitaxel and sirolimus-based formulations, have significantly improved clinical outcomes, supporting adoption across healthcare settings. The growing demand for minimally invasive and cost-effective alternatives to stenting also boosts market growth. Additionally, favorable reimbursement policies in developed countries and a rise in awareness about PAD and its treatment options further fuel demand for DEBs.

Market Restraints:

Despite strong growth potential, the market faces challenges including stringent regulatory requirements for product approvals, particularly concerning the safety and efficacy of drug coatings. Recent controversies over paclitaxel-coated devices and their long-term safety have raised concerns among clinicians and regulatory bodies, impacting adoption rates. Moreover, high device costs and limited reimbursement in developing regions restrict widespread use. The presence of alternative treatment modalities, such as bare balloons and stents, also poses competitive pressure on the market.

Market Opportunities:

The peripheral drug eluting balloons market presents significant opportunities driven by innovation in coating technologies, expansion into emerging markets, and integration with imaging and navigation technologies for enhanced procedural outcomes. Development of next-generation DEBs with improved drug release profiles and biocompatible materials can capture new demand. Increasing investment in clinical trials and collaboration with research institutions are expected to generate robust data supporting broader clinical use. Moreover, growing healthcare infrastructure in Asia-Pacific and Latin America opens new avenues for market penetration and growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the peripheral drug eluting balloons market globally?
  • Which drug types and anatomical applications are influencing product development and adoption?
  • How are regulatory frameworks and safety concerns shaping market trends and clinical usage?
  • Who are the leading companies in the peripheral DEBs market, and what strategies are they employing to strengthen their competitive positioning?
  • What are the emerging trends and long-term growth prospects across different regions?

Competitive Intelligence and Business Strategy:

These companies are investing in the development of new drug formulations, biodegradable coatings, and balloons with improved deliverability and precision. Collaborations with academic institutions and clinical centers enable real-world validation and product optimization. Expansion into emerging markets through distribution agreements and regulatory approvals plays a critical role in capturing untapped demand and diversifying revenue streams.

Key Companies Profiled:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Cook Medical Inc.
  • MicroPort Scientific Corporation (Endovastec(TM))
  • Medtronic Plc.
  • Cardinal Health, Inc.
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Becton, Dickinson and Company
  • W. L. Gore & Associates Inc.
  • Getinge AB
  • Terumo Corp
  • Kyoto Medical Planning Co Ltd
  • iVascular S.L.U
  • AMG International GmbH
  • ENDOCOR GmbH
  • Meril Life Sciences Pvt. Ltd.
  • Nano Therapeutics Pvt Ltd
  • Koninklijke Philips N.V.
  • REVA Medical

Peripheral Drug Eluting Balloons Market Research Segmentation:

Drug Coating:

  • Paclitaxel Drug Coating
  • Sirolimus drug Coating
  • Others

Indication:

  • Peripheral Arterial Disease
  • Peripheral Aneurysms
  • In-Stent Restenosis
  • Others

Artery Type:

  • Carotid Arteries
  • Fem-Pop Arteries
  • Iliac Arteries
  • Infrapop Arteries

End User:

  • Hospitals
  • Ambulatory Surgical Centers/Outpatients
  • Cardiac Catheterization Labs

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Peripheral Drug Eluting Balloons Market Snapshot 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Industry Developments and Key Market Events
  • 1.5. Demand Side and Supply Side Analysis
  • 1.6. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definitions
  • 2.2. Value Chain Analysis
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global GDP Outlook
    • 2.3.2. Global Construction Industry Overview
    • 2.3.3. Global Mining Industry Overview
  • 2.4. Forecast Factors - Relevance and Impact
  • 2.5. COVID-19 Impact Assessment
  • 2.6. PESTLE Analysis
  • 2.7. Porter's Five Forces Analysis
  • 2.8. Geopolitical Tensions: Market Impact
  • 2.9. Regulatory and Technology Landscape

3. Market Dynamics

  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Opportunities
  • 3.4. Trends

4. Price Trend Analysis, 2019-2032

  • 4.1. Region-wise Price Analysis
  • 4.2. Price by Segments
  • 4.3. Price Impact Factors

5. Global Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 5.1. Key Highlights
  • 5.2. Global Peripheral Drug Eluting Balloons Market Outlook: Drug Coating
    • 5.2.1. Introduction/Key Findings
    • 5.2.2. Historical Market Size (US$ Mn) Analysis by Drug Coating, 2019-2024
    • 5.2.3. Current Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
      • 5.2.3.1. Paclitaxel Drug Coating
      • 5.2.3.2. Sirolimus drug Coating
    • 5.2.4. Market Attractiveness Analysis: Drug Coating
  • 5.3. Global Peripheral Drug Eluting Balloons Market Outlook: Indication
    • 5.3.1. Introduction/Key Findings
    • 5.3.2. Historical Market Size (US$ Mn) Analysis by Indication, 2019-2024
    • 5.3.3. Current Market Size (US$ Mn) Forecast, by Indication, 2025-2032
      • 5.3.3.1. Peripheral Arterial Disease
      • 5.3.3.2. Peripheral Aneurysms
      • 5.3.3.3. In-Stent Restenosis
    • 5.3.4. Market Attractiveness Analysis: Indication
  • 5.4. Global Peripheral Drug Eluting Balloons Market Outlook: Artery Type
    • 5.4.1. Introduction/Key Findings
    • 5.4.2. Historical Market Size (US$ Mn) Analysis by Artery Type, 2019-2024
    • 5.4.3. Current Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
      • 5.4.3.1. Carotid Arteries
      • 5.4.3.2. Fem-Pop Arteries
      • 5.4.3.3. Iliac Arteries
      • 5.4.3.4. Infrapop Arteries
    • 5.4.4. Market Attractiveness Analysis: Artery Type
  • 5.5. Global Peripheral Drug Eluting Balloons Market Outlook: End User
    • 5.5.1. Introduction/Key Findings
    • 5.5.2. Historical Market Size (US$ Mn) Analysis by End User, 2019-2024
    • 5.5.3. Current Market Size (US$ Mn) Forecast, by End User, 2025-2032
      • 5.5.3.1. Hospitals
      • 5.5.3.2. Ambulatory Surgical Centers/Outpatients
      • 5.5.3.3. Cardiac Catheterization Labs
    • 5.5.4. Market Attractiveness Analysis: End User

6. Global Peripheral Drug Eluting Balloons Market Outlook: Region

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2024
  • 6.3. Current Market Size (US$ Mn) Forecast, by Region, 2025-2032
    • 6.3.1. North America
    • 6.3.2. Europe
    • 6.3.3. East Asia
    • 6.3.4. South Asia & Oceania
    • 6.3.5. Latin America
    • 6.3.6. Middle East & Africa
  • 6.4. Market Attractiveness Analysis: Region

7. North America Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. North America Market Size (US$ Mn) Forecast, by Country, 2025-2032
    • 7.3.1. U.S.
    • 7.3.2. Canada
  • 7.4. North America Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
    • 7.4.1. Paclitaxel Drug Coating
    • 7.4.2. Sirolimus drug Coating
  • 7.5. North America Market Size (US$ Mn) Forecast, by Indication, 2025-2032
    • 7.5.1. Peripheral Arterial Disease
    • 7.5.2. Peripheral Aneurysms
    • 7.5.3. In-Stent Restenosis
  • 7.6. North America Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
    • 7.6.1. Carotid Arteries
    • 7.6.2. Fem-Pop Arteries
    • 7.6.3. Iliac Arteries
    • 7.6.4. Infrapop Arteries
  • 7.7. North America Market Size (US$ Mn) Forecast, by End User, 2025-2032
    • 7.7.1. Hospitals
    • 7.7.2. Ambulatory Surgical Centers/Outpatients
    • 7.7.3. Cardiac Catheterization Labs

8. Europe Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Europe Market Size (US$ Mn) Forecast, by Country, 2025-2032
    • 8.3.1. Germany
    • 8.3.2. Italy
    • 8.3.3. France
    • 8.3.4. U.K.
    • 8.3.5. Spain
    • 8.3.6. Russia
    • 8.3.7. Rest of Europe
  • 8.4. Europe Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
    • 8.4.1. Paclitaxel Drug Coating
    • 8.4.2. Sirolimus drug Coating
  • 8.5. Europe Market Size (US$ Mn) Forecast, by Indication, 2025-2032
    • 8.5.1. Peripheral Arterial Disease
    • 8.5.2. Peripheral Aneurysms
    • 8.5.3. In-Stent Restenosis
  • 8.6. Europe Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
    • 8.6.1. Carotid Arteries
    • 8.6.2. Fem-Pop Arteries
    • 8.6.3. Iliac Arteries
    • 8.6.4. Infrapop Arteries
  • 8.7. Europe Market Size (US$ Mn) Forecast, by End User, 2025-2032
    • 8.7.1. Hospitals
    • 8.7.2. Ambulatory Surgical Centers/Outpatients
    • 8.7.3. Cardiac Catheterization Labs

9. East Asia Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. East Asia Market Size (US$ Mn) Forecast, by Country, 2025-2032
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. South Korea
  • 9.4. East Asia Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
    • 9.4.1. Paclitaxel Drug Coating
    • 9.4.2. Sirolimus drug Coating
  • 9.5. East Asia Market Size (US$ Mn) Forecast, by Indication, 2025-2032
    • 9.5.1. Peripheral Arterial Disease
    • 9.5.2. Peripheral Aneurysms
    • 9.5.3. In-Stent Restenosis
  • 9.6. East Asia Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
    • 9.6.1. Carotid Arteries
    • 9.6.2. Fem-Pop Arteries
    • 9.6.3. Iliac Arteries
    • 9.6.4. Infrapop Arteries
  • 9.7. East Asia Market Size (US$ Mn) Forecast, by End User, 2025-2032
    • 9.7.1. Hospitals
    • 9.7.2. Ambulatory Surgical Centers/Outpatients
    • 9.7.3. Cardiac Catheterization Labs

10. South Asia & Oceania Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. South Asia & Oceania Market Size (US$ Mn) Forecast, by Country, 2025-2032
    • 10.3.1. India
    • 10.3.2. Southeast Asia
    • 10.3.3. ANZ
    • 10.3.4. Rest of SAO
  • 10.4. South Asia & Oceania Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
    • 10.4.1. Paclitaxel Drug Coating
    • 10.4.2. Sirolimus drug Coating
  • 10.5. South Asia & Oceania Market Size (US$ Mn) Forecast, by Indication, 2025-2032
    • 10.5.1. Peripheral Arterial Disease
    • 10.5.2. Peripheral Aneurysms
    • 10.5.3. In-Stent Restenosis
  • 10.6. South Asia & Oceania Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
    • 10.6.1. Carotid Arteries
    • 10.6.2. Fem-Pop Arteries
    • 10.6.3. Iliac Arteries
    • 10.6.4. Infrapop Arteries
  • 10.7. South Asia & Oceania Market Size (US$ Mn) Forecast, by End User, 2025-2032
    • 10.7.1. Hospitals
    • 10.7.2. Ambulatory Surgical Centers/Outpatients
    • 10.7.3. Cardiac Catheterization Labs

11. Latin America Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 11.1. Key Highlights
  • 11.2. Pricing Analysis
  • 11.3. Latin America Market Size (US$ Mn) Forecast, by Country, 2025-2032
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of LATAM
  • 11.4. Latin America Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
    • 11.4.1. Paclitaxel Drug Coating
    • 11.4.2. Sirolimus drug Coating
  • 11.5. Latin America Market Size (US$ Mn) Forecast, by Indication, 2025-2032
    • 11.5.1. Peripheral Arterial Disease
    • 11.5.2. Peripheral Aneurysms
    • 11.5.3. In-Stent Restenosis
  • 11.6. Latin America Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
    • 11.6.1. Carotid Arteries
    • 11.6.2. Fem-Pop Arteries
    • 11.6.3. Iliac Arteries
    • 11.6.4. Infrapop Arteries
  • 11.7. Latin America Market Size (US$ Mn) Forecast, by End User, 2025-2032
    • 11.7.1. Hospitals
    • 11.7.2. Ambulatory Surgical Centers/Outpatients
    • 11.7.3. Cardiac Catheterization Labs

12. Middle East & Africa Peripheral Drug Eluting Balloons Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

  • 12.1. Key Highlights
  • 12.2. Pricing Analysis
  • 12.3. Middle East & Africa Market Size (US$ Mn) Forecast, by Country, 2025-2032
    • 12.3.1. GCC Countries
    • 12.3.2. South Africa
    • 12.3.3. Northern Africa
    • 12.3.4. Rest of MEA
  • 12.4. Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Coating, 2025-2032
    • 12.4.1. Paclitaxel Drug Coating
    • 12.4.2. Sirolimus drug Coating
  • 12.5. Middle East & Africa Market Size (US$ Mn) Forecast, by Indication, 2025-2032
    • 12.5.1. Peripheral Arterial Disease
    • 12.5.2. Peripheral Aneurysms
    • 12.5.3. In-Stent Restenosis
  • 12.6. Middle East & Africa Market Size (US$ Mn) Forecast, by Artery Type, 2025-2032
    • 12.6.1. Carotid Arteries
    • 12.6.2. Fem-Pop Arteries
    • 12.6.3. Iliac Arteries
    • 12.6.4. Infrapop Arteries
  • 12.7. Middle East & Africa Market Size (US$ Mn) Forecast, by End User, 2025-2032
    • 12.7.1. Hospitals
    • 12.7.2. Ambulatory Surgical Centers/Outpatients
    • 12.7.3. Cardiac Catheterization Labs

13. Competition Landscape

  • 13.1. Market Share Analysis, 2025
  • 13.2. Market Structure
    • 13.2.1. Competition Intensity Mapping
    • 13.2.2. Competition Dashboard
  • 13.3. Company Profiles
    • 13.3.1. Abbott Laboratories
      • 13.3.1.1. Company Overview
      • 13.3.1.2. Product Portfolio/Offerings
      • 13.3.1.3. Key Financials
      • 13.3.1.4. SWOT Analysis
      • 13.3.1.5. Company Strategy and Key Developments
    • 13.3.2. Boston Scientific Corporation
    • 13.3.3. Cook Medical Inc.
    • 13.3.4. MicroPort Scientific Corporation (Endovastec(TM))
    • 13.3.5. Medtronic Plc.
    • 13.3.6. Cardinal Health, Inc.
    • 13.3.7. B. Braun Melsungen AG
    • 13.3.8. BIOTRONIK SE & Co. KG
    • 13.3.9. Becton, Dickinson and Company
    • 13.3.10. W. L. Gore & Associates Inc.
    • 13.3.11. Getinge AB
    • 13.3.12. Terumo Corp
    • 13.3.13. Kyoto Medical Planning Co Ltd
    • 13.3.14. iVascular S.L.U
    • 13.3.15. AMG International GmbH

14. Appendix

  • 14.1. Research Methodology
  • 14.2. Research Assumptions
  • 14.3. Acronyms and Abbreviations
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦